Objective To observe the therapeutic effect of Qiyao Xiaoke Capsule(Capsule for Diabetes) on the diabetes type Ⅱ.Methods Totally 240 diabetes type Ⅱ patients were randomized into a treatment group(n=150),and a control group(n=90);and other 30 diabetes patients who didn't regularly take hypoglycemic drugs were set as opening group.The treatment group was administered Qiyao Xiaoke Capsule plus Metformin Hydrochloride Tablets,while the control group was prescribed Xiaokeling Capsule in addition to Metformin Hydrochloride Tablets,and the opening group was given Qiyao Xiaoke Capsule only,with a leading period of two weeks.The patients were treated for 4 weeks.Before treatment and at the end of the 4 weeks' treatment,the fasting blood glucose(FBG),2 hours postprandial blood glucose(2hPG),and glycosylated hemoglobin(HbA1c) of all groups were determined,and scores of TCM syndromes and symptoms were observed to evaluate the therapeutic effect.Results The total effective rate of the treatment group was 74.67%,of the control group 72.22%,and in the opening group 70.00%.Except for the 2hPG of the opening group,the FBG,2hPG and HbA1c of 3 groups were decreased(P

OBJECTIVE: To optimize the preparation technology of Buqi tongmai capsule.METHODS: Orthogonal experiment of exeracting Radix Astragali was conducted with crude drugs soaking time,extracting times,amount of water added and decocting duration as factors and the content of astragaloside as index.Orthogonal experiment of exeracting Salvia miltiorrhiza,Ligusticum chuanxiong,Fructus Aurantii Immaturus,Carthamus tinctorius was conducted with crude drugs soaking time,amount of water added and decocting duration as factors and the content of tanshinol as index.RESULTS:Water was adopted for extraction and the concentration of alcohol for precipitate was 70 percent.The optimal technology of exeracting Radix Astragali was to soak the crude drugs for 30 min,decoct for 90 min in 10 times of water for 2 times.The optimal technology of exeracting S.miltiorrhiza,L.chuanxiong,Fructus Aurantii Immaturus,C.tinctorius was to decoct the crude drugs for 90 min,8 times of water for 2 times.CONCLUSION:The preparation processes is feasible,stable and meet the demands in the clinic.

Objective To evaluate the expression and its clinical significance of serum LCN-2 and MMP-9 in human breast cancer.Methods 96 patients with breast cancer,42 patients with benign breast diseases and 27 healthy controls were recrui-ted in this study.The LCN-2 and MMP-9 levels were measured by ELISA in the serum of 96 patients with breast cancer,42 patients with benign breast disease,and 27 health controls.Results The level of serum LCN-2 in the breast cancer group (89.76±28.38 ng/ml)was significantly higher than those in benign breast diseases (56.44±21.15 ng/ml)and healthy controls (44.32±16.84 ng/ml)(P<0.05).The level of serum MMP-9 in the breast cancer group (96.34±23.26 ng/ml) was significantly higher than those in benign breast diseases (28.16±11.57 ng/ml)and healthy controls (23.54±13.61 ng/ml)(P<0.05).No obvious difference in the levels of serum LCN-2 and MMP-9 was observed between benign breast disease and healthy controls (P>0.05).Correlation analysis showed that a positive correlation was found between the levels of serum LCN-2 and MMP-9 in breast cancer patients (r=0.513 5,P<0.05).The levels of serum LCN-2 and MMP-9 were significantly associated with tumor size,lymph node metastasis,the expression of ER and PR,TNM stage,but were not asso-ciated with tumor differentiation (P>0.05).The correlation analysis showed that the LCN-2 level was positive correlated with the MMP-9 level (P<0.05).Conclusion LCN-2 and MMP-9 could play a role in the tumorigenesis and development of breast cancer.Measuring of serum LCN-2 and MMP-9 may be a useful tool for diagnosis,effect monitoring and prognosis in breast cancer.

Cells, Cultured ; Endothelial Cells ; drug effects ; metabolism ; Endothelium, Vascular ; cytology ; metabolism ; Gene Expression Profiling ; Humans ; Ouabain ; pharmacology ; Umbilical Veins ; cytology

Objective To perform literature search and review on the controversial relationship between therapies of hyperthyroidism due to Graves'disease(GD)and the course of Graves'ophthalmopathy(CA)).Methods We searched the database of MEDLINE(1966-2006.3),EMBASE(1984-2005),Cochrane Library(2006 No.1),CBMdisc(1978.1-2006.4)and CNKI(1994-2006).The methodological quality of the studies selected for review was assessed according to the quality assessment criteria suggested by the Cochrane systematic review guideline.Meta-analysis was performed by RevMan 4.2 software.Results Eight studies were included in the systematic review.Meta-analysis showed that there was statistically significant difference between 131I and other forms of therapy[surgery or antithyroid drugs(ATD)](test value:2.31,5.97,3.70,5.55;all P＜0.05)in aggravation of exophthalmos and symptom improvement in patients without receiving thyroxine during the early stage to prevent hypothyroidism.However,there was no statisti cally significant differenee in the above relationship between surgery and ATD therapy in those patients already receiving thyroxine supplement(test value:0.27,0.99;all P＞0.05).There were not yet any studies on the impact between early prevention of hypothyroidism after 131I therapy and GO.Conclusions Based on meta-analysis on literature data,if early measures are not performed to prevent hypothyroidism after 131I therapy,it may induce or aggravate GO more frequently than ATD or surgical treatment.Symptomatic relief of GO after 131I therapy is also less effective than the other 2 forms of therapy.Therefore.131I therapy should be delivered carefully in those patients with GO.

OBJECTIVE: To investigate the pharmacokinetics of cefazedone sodium in Chinese healthy volunteers after a single or multiple dose of intravenous drip infusion. METHODS: Thirty healthy volunteers, half male and half female, were randomly assigned to three groups of single dose and one group of multiple dose. The plasma drug concentrations after intravenous drip of single dose of 0.5, 1.0, 2.0 g and multiple dose of 1.0 g cefazedone sodium were determined by HPLC-MS/MS. RESULTS: The pharmacokinetic parameters of cefazedone sodium after single dose of 0.5, 1.0, 2.0 g were obtained as follows: t1/2z were (1.85 ± 0.53), (1.81 ± 0.29), (2.07 ± 0.32) h, respectively; AUC0-t were (145.30 ± 68.67), (244.26 ± 38.284), (513.10 ± 127.27) mg · h · L-1; AUC0-∞ were (147.89 ± 70.45), (246.60 ± 40.61), (521.02 ± 134.33) mg · h · L-1; tmax were (0.30 ± 0.06), (0.33 ± 0.00), (0.35 ± 0.05) h; ρmax were(87.18 ± 36.37), (151.13 ± 19.02), (271.94 ± 38.86) mg · L-1; Vz were (9.97 ± 2.91), (10.67 ± 1.27), (11.75 ± 1.78) L, CLz were (3.88 ± 1.239), (4.14 ± 0.57), (4.03 ± 0.86) L · h-1, respectively. The multi-dose pharmacokinetic parameters of cefazedone sodium were obtained as follows: AUCss was (208.93 ± 37.37) mg · h · L-1; AUC0-t was (208.93 ± 37.37) mg · h · L-1; AUC0-∞ was (210.64 ± 38.55) mg · h · L-1; tmax was (0.33 ± 0.00) h; ρmax was(130.20 ± 22. 83)mg · L-1; ρss was (17.41 ± 3.11) mg · L-1; ρmin was (0.89 ± 0.60) mg · L-1; DF was (7.45 ± 0.70); t1/2z was(1.77 ± 0.25) h; Vz was (12.40 ± 2.57) L; CLz was (4.90 ± 0.95) L · h-1. CONCLUSION: Cefazedone sodium displays linear pharmacokinetics in the dose range of 0.5 to 2 g after single intravenous drip injection. No significant differences between genders are observed. The differences of the main pharmacokinetic parameters of tmax, t1/2z, Vz and CLz between each group are not significant (P > 0.05). There is no significant accumulation of cefazedone sodium in healthy volunteers after multiple intravenous drip injection. Copyright 2012 by the Chinese Pharmaceutical Association.

Adult ; Aged ; Aged, 80 and over ; Carbon Monoxide Poisoning ; complications ; Female ; Humans ; Interleukins ; blood ; Male ; Middle Aged ; Neurotoxicity Syndromes ; blood ; etiology

Abdominal Pain ; etiology ; Child, Preschool ; Humans ; Male ; Porphyria, Acute Intermittent ; complications ; diagnosis ; therapy ; Prognosis ; Treatment Outcome

China ; Clinical Protocols ; Hospital Units ; Humans ; Physicians ; Thrombocytopenia ; diagnosis ; therapy

China ; Environmental Exposure ; Heat Stress Disorders ; prevention & control ; Industry ; Occupational Health ; Temperature ; Workplace